New Delhi, Sept 13: A new blood test has effectively screened for numerous cancers in people who had not yet manifested any symptoms, which has the potential to revolutionize medical science. As part of a Pathfinder Study, the test was administered to 6,662 people by GRAIL, a healthcare organisation focusing on enhancing cancer detection.
Patients 50 years of age and older were subjected to the test since they have a higher chance of developing cancer. At the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, the test findings were revealed.
About 1% of individuals in the research had cancer, including forms for which there is no reliable screening tool. The test’s results have never been published prior to now. Both an earlier version of Galleri (MCED-E) and a more advanced version of Galleri were used to measure the Multi-Cancer Early Detection (MCED) test (MCED-Scr).
The prior iteration of the test, according to researchers, was improved to decrease the identification of pre-malignant hematologic disorders, which are rather common, and enhance the prediction of the origin of the cancer signal.
35 participants out of 92 patients who had the cancer signal were diagnosed with 36 different types of cancer. According to the business, 71% of participants had cancer forms for which there is no available regular cancer screening.
Additionally, they found that the cancer signal origin prediction was 97% accurate, and that for the majority of subjects, the cancer diagnosis was resolved in less than three months following therapeutic treatment.
The new test is probably going to improve cancer screening and develop better treatment plans sooner than anticipated. Following true and false-positive results, participants underwent imaging procedures like scans or MRIs, and the majority of true positive participants (82%) underwent an invasive procedure to confirm a cancer diagnosis.